Generic Auvi-Q Availability
Last updated on Apr 10, 2025.
Auvi-Q is a brand name of epinephrine, approved by the FDA in the following formulation(s):
AUVI-Q (epinephrine - solution;intramuscular, subcutaneous)
-
Manufacturer: KALEO INC
Approval date: August 10, 2012
Strength(s): EQ 0.15MG/DELIVERY [RLD] [BX], EQ 0.3MG/DELIVERY [RLD] [BX] -
Manufacturer: KALEO INC
Approval date: November 17, 2017
Strength(s): EQ 0.1MG/DELIVERY [RLD]
Is there a generic version of Auvi-Q available?
No. There is currently no therapeutically equivalent version of Auvi-Q available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auvi-Q. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Devices, systems and methods for medicament delivery
Patent 10,335,549
Issued: July 2, 2019
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F.
Assignee(s): kaleo, Inc.A method includes moving an actuation lock of a medical injector from a first position to a second position. The actuation lock has an extended portion disposed between a shoulder of a housing and the base when the actuation lock is in the first position. The extended portion is spaced apart from the base when the actuation lock is in the second position. A distal end portion of a base, which is movably coupled to an end portion of the housing, is placed into contact with a body. The base is actuated after the placing to release an energy from an energy storage member within the housing to produce a force to move a needle from a first needle position to a second needle position. At least a portion of the needle extends through the base when the needle is in the second needle position.
Patent expiration dates:
- April 30, 2025✓
- April 30, 2025
-
Medicament delivery device and methods for delivering drugs to infants and children
Patent 10,688,244
Issued: June 23, 2020
Inventor(s): Edwards Eric S. & Edwards Evan T. & Kelley Glen L. & Meyers Paul F.
Assignee(s): kaleo, Inc.A method of delivering epinephrine includes placing a distal end surface of a medical injector into contact with a target location of a patient. The medical injector includes a housing, an energy storage member, and a medicament container containing a dose of epinephrine effective for administration to the patient experiencing anaphylaxis and having a weight of less than 15 kg. The medicament container is coupled to a needle. The medical injector is actuated such that the energy storage member produces a force to move the needle from a first needle position to a second needle position. A distal tip of the needle extends from the distal end surface by a distance of between 7 millimeters and 8 millimeters when the needle is in the second needle position. A portion of the force is exerted to expel the dose of epinephrine when the needle is in the second position.
Patent expiration dates:
- December 21, 2037✓✓
- December 21, 2037
-
Medicament delivery device and methods for delivering drugs to infants and children
Patent 10,842,938
Issued: November 24, 2020
Inventor(s): Edwards Eric S. & Edwards Evan T. & Kelley Glen L. & Meyers Paul F.
Assignee(s): kaleo, Inc.A method of delivering epinephrine includes placing a distal end surface of a medical injector into contact with a target location of a patient. The medical injector includes a housing, an energy storage member, and a medicament container containing a dose of epinephrine effective for administration to the patient experiencing anaphylaxis and having a weight of less than 15 kg. The medicament container is coupled to a needle. The medical injector is actuated such that the energy storage member produces a force to move the needle from a first needle position to a second needle position. A distal tip of the needle extends from the distal end surface by a distance of between 7 millimeters and 8 millimeters when the needle is in the second needle position. A portion of the force is exerted to expel the dose of epinephrine when the needle is in the second position.
Patent expiration dates:
- December 21, 2037✓✓
- December 21, 2037
-
Devices, systems and methods for medicament delivery
Patent 11,590,286
Issued: February 28, 2023
Inventor(s): Edwards; Eric S. et al.
Assignee(s): kaleo, Inc. (Richmond, VA)A method includes moving an actuation lock of a medical injector from a first position to a second position. The actuation lock has an extended portion disposed between a shoulder of a housing and the base when the actuation lock is in the first position. The extended portion is spaced apart from the base when the actuation lock is in the second position. A distal end portion of a base, which is movably coupled to an end portion of the housing, is placed into contact with a body. The base is actuated after the placing to release an energy from an energy storage member within the housing to produce a force to move a needle from a first needle position to a second needle position. At least a portion of the needle extends through the base when the needle is in the second needle position.
Patent expiration dates:
- December 12, 2026✓
- December 12, 2026
-
Medicament delivery device and methods for delivering drugs to infants and children
Patent 11,771,830
Issued: October 3, 2023
Inventor(s): Edwards; Eric S. et al.
Assignee(s): kaleo, Inc. (Richmond, VA)A method of delivering epinephrine includes placing a distal end surface of a medical injector into contact with a target location of a patient. The medical injector includes a housing, an energy storage member, and a medicament container containing a dose of epinephrine effective for administration to the patient experiencing anaphylaxis and having a weight of less than 15 kg. The medicament container is coupled to a needle. The medical injector is actuated such that the energy storage member produces a force to move the needle from a first needle position to a second needle position. A distal tip of the needle extends from the distal end surface by a distance of between 7 millimeters and 8 millimeters when the needle is in the second needle position. A portion of the force is exerted to expel the dose of epinephrine when the needle is in the second position.
Patent expiration dates:
- December 21, 2037✓✓
- December 21, 2037
-
Devices, systems and methods for medicament delivery
Patent 7,947,017
Issued: May 24, 2011
Inventor(s): Edwards; Evan Thomas et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
Patent expiration dates:
- March 12, 2028✓
- March 12, 2028
-
Medicament delivery device configured to produce an audible output
Patent 8,021,344
Issued: September 20, 2011
Inventor(s): Edwards; Eric S. et al.
Assignee(s): Intelliject, Inc. (Richmond, VA)Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medicament delivery device and an electronic circuit system. The medicament delivery device includes a housing, a medicament container, and a medicament delivery member. The electronic circuit system is coupled to the housing and includes an audible output device and a cover. The housing of the medicament delivery device and the cover of the electronic circuit system collectively define an acoustic enclosure. The audible output device is configured to be disposed within the acoustic enclosure.
Patent expiration dates:
- November 2, 2029✓
- November 2, 2029
-
Devices, systems and methods for medicament delivery
Patent 8,206,360
Issued: June 26, 2012
Inventor(s): Edwards Eric Shawn & Edwards Evan Thomas & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): Intelliject, Inc.An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Patent expiration dates:
- February 27, 2027✓
- February 27, 2027
-
Medical injector with compliance tracking and monitoring
Patent 8,226,610
Issued: July 24, 2012
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A. & Williamson & IV T. Spencer
Assignee(s): Intelliject, Inc.A system includes a medicament delivery device and a container configured to receive at least a portion of the medicament delivery device. The medicament delivery device includes an actuator and a first electronic circuit system. The actuator is configured to initiate delivery of a medicament into a body when the actuator is moved from a first position to a second position. The first electronic circuit system is configured to output a first electronic signal when the actuator is moved from the first position to the second position. The container includes a second electronic circuit system configured to receive the first electronic signal. The second electronic circuit system is configured to output a second electronic signal associated with the first electronic signal.
Patent expiration dates:
- April 10, 2029✓
- April 10, 2029
-
Medicament delivery device having an electronic circuit system
Patent 8,231,573
Issued: July 31, 2012
Inventor(s): Edwards Eric S. & Edwards Evan T. & Licata Mark J. & Meyers Paul F. & Weinzierl David A.
Assignee(s): Intelliject, Inc.Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector.
Patent expiration dates:
- November 25, 2028✓
- November 25, 2028
More about Auvi-Q (epinephrine)
- Check interactions
- Compare alternatives
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenergic bronchodilators
- Breastfeeding
Patient resources
Other brands
EpiPen, Adrenalin, Primatene Mist, neffy, ... +5 more
Professional resources
Other brands
EpiPen, Adrenalin, Primatene Mist, neffy, ... +4 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.